Current immunosuppressive treatment after kidney transplantation

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1217-1231

  Kho, Marcia ^a   Cransberg, Karlien ^b   Weimar, Willem ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

alemtuzumab; antithymocyte globulin; basiliximab; calcineurin inhibitor; corticosteroids; immunosuppressive treatment; kidney transplantation; mTOR inhibitor; mycophenolate; pediatric

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BORTEZOMIB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DACLIZUMAB; ECULIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VOCLOSPORIN;

ACUTE GRAFT REJECTION; AVASCULAR NECROSIS; CARDIOVASCULAR RISK; CORTICOSTEROID THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENETIC POLYMORPHISM; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; REVIEW;

CALCINEURIN; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MULTICENTER STUDIES AS TOPIC;

EID: 79955787820     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.552428     Document Type: Review

References (116)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients.Am J Transplant 2009;9(Suppl 3):S1-155
2. Knight SR, Morris PJ.Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk.A meta-analysis.Transplantation 2010;89:1-14
3. Pascual J, Galeano C, Royuela A, Zamora J.A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation.Transplantation 2010;90:343-9
4. Steiner RW.In defence of steroids.Am J Transplantation 2005;5:2334-5
5. Burdmann EA, Andoh TF, Yu L, Bennet WM.Cyclosporine nephrotoxicity.Semin Nephrol 2003;23:465-76 (Pubitemid 37176692)
6. Schiff J, Cole E, Cantarovich M.Therapeutic monitoring of calcineurin inhibitors for the nephrologist.Clin J Am Soc Nephrol 2007;2:374-84
7. European Multicenter Trial Group.Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicenter trial.Lancet 1983;2:986-9
8. Canadian Multicenter Trial Group.A randomized clinical trial of cyclosporine in cadaveric renal transplantation.N Engl J Med 1983;309:809-15
9. Cole E, Keown P, Landsberg D, et al.Safety and tolerability of cyclosporine and CsA-ME during eighteen months of follow-up in stable renal transplant patients.Transplantation 1998;65:505-10 (Pubitemid 28136492)
10. Keown P, Niese D.Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation.Kidney Int 1998;54:938-44 (Pubitemid 28397413)
11. Burke JF, Pirsch JD, Ramos EL, et al.Long-term efficacy and safety of cyclosporine in renal transplant recipients.N Engl J Med 1994;331:358-63 (Pubitemid 24233855)
12. Myers BD, Ross J, Newton L, et al.Cyclosporine-associated chronic nephropathy.N Engl J Med 1984;311:699-70
13. Kopp JB, Klotman PE.Cellular and molecular mechanisms of cyclosporin nephrotoxicity.J Am Soc Nephrol 1990;1:162-79
14. van Hooff JP, Gelens M, Boots JM, et al.Preservation of renal function and cardiovascular risk factors.Transpl Proc 2006;38:1987-91 (Pubitemid 46068495)
15. Tanaka H, Kuroda A, Marusawa H, et al.Physicochemical properties of FK-506, a novel immunosuppressant isolated from streptomyces tsukubaensis.Transplant Proc 1987;19:S11-26
16. Ho S, Clipstone N, Timmermann L, et al.The mechanism of action of cyclosporine A and FK-506.Clin Immunol Immunopathol 1996;80:S40-5
17. Lemahieu W, Maes B, Verbeke K, et al.Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.Am J Transpl 2005;5:1383-91 (Pubitemid 40839429)
18. Van Gelder T, Hesselink DA.Dosing tacrolimus based on CYPA5 genotype: will it improve clinical outcome? Clin Pharmacol Ther 2010;87:640-1
19. Kramer BK, Montagnino G, del Castillo D, et al.Efficacy and safety of tacrolimus compared with cyclosporine- microemulsion in renal transplantation: 2 year follow-up results.Nephrol Dial Transplant 2005;20:968-73 (Pubitemid 40704035)
20. Hardinger KL, Bohl DL, Schnitzler MA, et al.A randomized, prospective, pharmaco-economic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients.Transplantation 2005;80:41-6 (Pubitemid 40980893)
21. Vincenti F, Friman S, Scheuermann E, et al.Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.Am J Transplant 2007;7:1506-14 (Pubitemid 46776239)
22. Ekberg H, Tedesco-Silva H, Demirbas A, et al.Reduced exposure to calcineurin inhibitors in renal transplantation.N Engl J Med 2007;357:2562-75 (Pubitemid 350294223)
23. Webster AC, Woodroffe RC, Taylor RS, et al.Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data.BMJ 2005;331:810-20
24. Opelz G, Dohler B.Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.Transplantation 2009;87:795-802
25. Alloway R, Steinberg S, Khalil K, et al.Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release Tacrolimus-based regimen.Transplant Proc 2005;37:867-70 (Pubitemid 40590728)
26. Alloway R, Steinberg S, Khalil K, et al.Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.Transplantation 2007;83:1648-51 (Pubitemid 46987920)
27. Kramer BK, Charpentier B, Backman L, et al.Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.Am J Transplant 2010;10:2632-43
28. De Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y.Reduced CO concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation.Transplantation 2010;90:523-9
29. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al.Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.Am J Transplant 2009;9:2505-13
30. Papp K, Bissonnette R, Rosoph L, et al.Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.Lancet 2008;371:1337-42 (Pubitemid 351522314)
31. Anglade E, Aspeslet LJ, Weiss SL.A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin.Clin Ophthalmol 2008;2:693-702
32. Gregory CR, Kyles AE, Bernsteen L, et al.Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model.Transplantation 2004;78:681-5 (Pubitemid 39244728)
33. Barten MJ, van Gelder T, Gummert JF, et al.Novel assays of multiple lymphocyte functions in whole blood measure.New mechanisms of action of mycophenolate mofetil in vivo.Transplant Immunol 2002;10:1-14 (Pubitemid 34863319)
34. Barten MJ, van Gelder T, Gummert JF, et al.Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection.Am J Transplant 2002;2:719-32 (Pubitemid 36342615)
35. Morris RE, Hoyt EG, Eugui EM, et al.Prolongation of rat heart allograft survival by RS-61443.Surgical Forum 1989;40:337-8 (Pubitemid 20156504)
36. Morris RE, Hoyt EG, Murphy MP, et al.Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis.Transpl Proc 1990;22:1659-62 (Pubitemid 20284486)
37. European Mycophenolate Mofetil Cooperative Study Group.Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection.Lancet 1995;345:1321-5
38. The Tricontinental Mycohenolate Mofetil Renal Transplantation Study Group.A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation.Transplantation 1996;61:1029-37
39. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group.Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients.Transplantation 1995;60:225-32
40. Halloran P, Mathew T, Tomlanovich S, et al.Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection.The International Mycophenolate Mofetil Renal Transplant Study Groups.Transplantation 1997;63:39-47 (Pubitemid 27036687)
41. Shapiro R, Jordan ML, Scantlebury VL, et al.A prospective randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.Transplantation 1999;67:411-16
42. Budde K, Curtis J, Knoll G, et al.Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.Am J Transplant 2004;4:237-43 (Pubitemid 38248527)
43. Salvadori M, Holzer H, de Mattos A, et al.Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.Am J Transplant 2004;4:231-6 (Pubitemid 38248526)
44. Moore J, Middleton L, Cockwell P, et al.Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.Transplantation 2009;87:591-605
45. Grinyo JM, Cruzado JM.Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress.Am J Transplant 2009;9:2447-52
46. Sehgal SN.Sirolimus: its discovery, biological properties, and mechanism of action.Transpl Proc 2003;35(Suppl 3A):7S-14S (Pubitemid 36547910)
47. Kahan BD.Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study.The Rapamune US Study Group.Lancet 2000;356:194-202 (Pubitemid 30446974)
48. MacDonald AS.A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.The Rapamune Global Study Group.Transplantation 2001;71:271-80 (Pubitemid 32126112)
49. Podder H, Stepkowski SM, Napoli KL, et al.Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.J Am Soc Nephrol 2001;12:1059-71 (Pubitemid 32378348)
50. Oberbauer R, Kreis H, Johnson RW, et al.Rapamune Maintenance Regimen Group.Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.Transplantation 2003;76:364-70 (Pubitemid 36928000)
51. Flechner SM, Goldfarb D, Modlin C, et al.Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.Transplantation 2002;74:1070-6 (Pubitemid 35216097)
52. van den Akker JM, Hene RJ, Hoitsma AJ.Inferior results with basis immunosuppression with sirolimus in kidney transplantation.Neth J Med 2007;65:23-8 (Pubitemid 46152291)
53. Gelens MA, Christiaans MH, van Heurn EL, et al.High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation.Transplantation 2006;82:1221-3 (Pubitemid 44748026)
54. Lebranchu Y, Thierry A, Toupance O, et al.Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.Am J Transplant 2009;9:1115-23
55. Schena FP, Pascoe MD, Alberu J, et al.Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.Transplantation 2009;87:233-42
56. Schuler W, Sedrani R, Cottens S, et al.SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo.Transplantation 1997;64:36-42 (Pubitemid 27327197)
57. Vitko S, Margreiter R, Weimar W, et al.Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.Am J Transplant 2005;5:2521-30
58. Lorber MI, Mulgaonkar S, Butt KM, et al.Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.Transplantation 2005;80:244-52 (Pubitemid 41061682)
59. Chan L, Greenstein S, Hardy MA, et al.Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.Transplantation 2008;85:821-6 (Pubitemid 351440746)
60. De Simone P, Metselaar HJ, Fischer L, et al.Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.Liver Transpl 2009;15:1262-9
61. Morales J, Fierro A, Benavente D, et al.Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.Transplantat Proc 2007;39:591-3 (Pubitemid 46574809)
62. clinicaltrial.gov identifier: NCT00154310
63. Rostaing L, Kamar N.mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010;23:133-42
64. Baboolal K.A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.Transplantation 2003;75:1404-8 (Pubitemid 36513057)
65. Nashan B, Curtis J, Ponticelli C, et al.Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.Transplantation 2004;78:1332-40 (Pubitemid 39507973)
66. Van Gurp E, Bustamante J, Franco A, et al.Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or MMF: results of a randomized multicenter trial in renal transplantation.J Transplant 2010.[Epub ahead of print]
67. Brennan DC, Daller JA, Lake KD, et al.Rabbit antithymocyte globulin versus basiliximab in renal transplantation.N Engl J Med 2006;355:1967-77 (Pubitemid 44708016)
68. Mohty M.Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.Leukemia 2007;21:1387-94 (Pubitemid 46965279)
69. Van Gelder T, Warle M, Ter Meulen RG.Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs 2004;64:1737-41 (Pubitemid 39215185)
70. Hale G.The CD52 antigen and development of the CAMPATH antibodies.Cytotherapy 2001;3:137-43 (Pubitemid 33039652)
71. Bloom DD, Hu HZ, Fechner JH, Knechtle SJ.T-lymphocyte alloresponses of campath-1H-treated kidney transplant patients.Transplantation 2006;81:81-7 (Pubitemid 43122153)
72. Szczech LA, Berlin JA, Aradhye S, et al.Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis.J Am Soc Nephrol 1997;8:1771-7 (Pubitemid 27475879)
73. Szczech LA, Berlin JA, Feldman HI.The effect of antilymphocyte induction therapy on renal allograft survival.A meta-analysis of individual patient-level data.Anti-Lymphocyte Antibody Induction Therapy Study Group.Ann Intern Med 1998;128:817-26 (Pubitemid 28267714)
74. Goggins WC, Pascual MA, Powelson JA, et al.A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients.Transplantation 2003;76:798-802 (Pubitemid 37140222)
75. Webster AC, Playford EG, Higgins G, et al.Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.Transplantation 2004;77:166-76 (Pubitemid 38155741)
76. Webster AC, Ruster LP, McGee R, et al.Interleukin 2 receptor antagonists for kidney transplant recipients.Cochrane Database Syst Rev 2010;1:CD003897
77. Ciancio G, Burke GW, Gaynor JJ, et al.A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate and steroid dosing and newer immune-monitoring.Transplantation 2005;80:457-65 (Pubitemid 41209412)
78. Ciancio G, Burke GW, Gaynor JJ, et al.A randomized trial of thymoglobulin vs.alemtuzumab (with lower dose maintenance immunosuppression) vs.daclizumab in renal transplantation at 24 months follow-up.Clin Transplant 2008;22:200-10 (Pubitemid 351420014)
79. Peddi R, Hanaway M, Woodle S, et al.Final 36 months results of a randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate and rapid stroid withdrawal in renal transplantation.Presented at the American Transplant Congress; 1-5 May 2010, San Diego, USA.
80. LaMattina JC, Mezrich JD, Hofmann M, et al.Alemtuzumab induction is associated with significant lower graft survival as compared to alternative contemporary induction regimens.Presented at the American Transplant Congress; 1-5 May 2010, San Diego, USA.
81. Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.Transplantation 2009;88:904-10
82. Meier-Kriesche H-U, Arndorfer JA, Kaplan B, et al.Association of antibody induction with short-and long-term cause-specific mortality in renal transplant recipients.J Am Soc Nephrol 2002;13:769
83. Durrbach A, Pestana JM, Pearson T, et al.A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).Am J Transplant 2010;10:547-57
84. Vincenti F, Charpentier B, Vanrenterghem Y, et al.A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).Am J Transplant 2010;10:535-46
85. Kaplan B.Belatacept: the promises and challenges of belatacept and costimulatory blockade.Am J Transplant 2010;10:441-2
86. FDA.Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/UCM201859.pdf.Bristol-Myers Squibb Company.Belatacept (BMS-224818).FDAs cardiovascular and renal drugs advisory committee.Briefing document for March 2010 meeting; 25 January 2010
87. Rostaing L, Massari P, Garcia VD, et al.Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase ii study.Clin J Am Soc Nephrol 2010.[Epub ahead of print]
88. Genberg H, Hansson A, Wernerson A, et al.Pharmacodynamics of rituximab in kidney allotransplantation.Am J Transplant 2006;6:2418-28 (Pubitemid 44359429)
89. Genberg H, Kumlien G, Wennberg L, et al.ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up.Transplantation 2008;85:1745-54
90. Tyden G, Genberg H, Tollemar J, et al.A randomized, double blind, placebo-controlled study of single-dose rituximab as induction in renal transplantation.Transplantation 2009;87:1325-9
91. Clatworthy MR, Watson CJE, Plotnek G, et al.B-cell depleting induction therapy and acute cellular rejection.N Engl J Med 2009;360:2683-5
92. Clinical Trials.gov number, NCT00565331
93. Rostaing L, Guilbeau-Frugier C, Kamar N.Rituximab for humoral rejection after kidney transplantation: an update.Transplantation 2009;87:1261
94. Loupy A, Suberbielle-Boisel C, Zuber J, et al.Combined posttransplant prophylactic IVIg/Anti-CD20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.Transplantation 2010;89:1403-10
95. Vo AA, Peng A, Toyoda M, et al.Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.Transplantation 2010;89:1095-102
96. Everly MJ, Everly JJ, Susskind B, et al.Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.Transplantation 2008;86:1754-61
97. Trivedi HL, Terasaki PI, Feroz A, et al.Abrogation of anti-HLA antibodies via proteasome inhibition.Transplantation 2009;87:1555-61
98. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al.Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.Am J Transplant 2010;10:681-6
99. Trivedi HL, Terasaki PI, Feroz A, et al.Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.Transplantation 2010;90:221-2
100. Zuber J, Le Quintrec M, Sberro-Soussan R, et al.New insights into postrenal transplant hemolytic uremic syndrome.Nat Rev Nephrol 2010.[Epub ahead of print]
101. Locke JE, Magro CM, Singer AL, et al.The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.Am J Transplant 2009;9:231-5
102. Smith JM, Stablein DM, Munoz R, et al.Contributions of the transplant registry: the 2006 annual report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS).Pediatr Transplant 2007;11:366-73 (Pubitemid 46671366)
103. Groothoff JW, Offringa M, Van Eck-Smit BL, et al.Severe bone disease and low bone mineral density after juvenile renal failure.Kidney Int 2003;63:266-75 (Pubitemid 35463930)
104. Hokken-Koelega AC, van Zaal MA, van Bergen W, et al.Final height and its predictive factors after renal transplantation in childhood.Pediatr Res 1994;36:323-8 (Pubitemid 24256779)
105. Fine RN, Ho M, Tejani A.The contribution of renal transplantation to final adult height: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).Pediatr Nephrol 2001;16:951-6 (Pubitemid 34026702)
106. Foster BJ, Martz K, Gowrishankar M, et al.Weight and height changes and factors associated with greater weight and height gains after pediatric renal transplantation: a NAPRTCS study.Transplantation 2010;89:1103-12
107. Broyer M, Guest G, Gagnadoux MF.Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation.J Pediatr 1992;120:721-5
108. Jabs K, Sullivan EK, Avner ED, Harmon WE.Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function.A report of the North American Pediatric Renal Transplant Cooperative Study.Transplantation 1996;61:31-6 (Pubitemid 26033374)
109. Grenda R, Watson A, Trompeter R, et al.A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study.Am J Transplant 2010;10:828-36
110. Hocker B, Weber LT, Feneberg R, et al.Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation.Nephrol Dial Transplant 2010;25:617-24
111. Sarwal MM, Vidhun JR, Alexander SR, et al.Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.Transplantation 2003;76:1331-9 (Pubitemid 37430720)
112. Cransberg K, Cornelissen M, Lilien M, et al.Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk.Transplantation 2007;83:1041-7 (Pubitemid 46659115)
113. Krischock L, Gullett A, Bockenhauer D, et al.Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.Pediatr Transplant 2009;13:475-81
114. Hocker B, Feneberg R, Kopf S, et al.SRL-based immunosuppression vs.CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.Pediatr Transplant 2006;10:593-601
115. Huyghe E, Zairi A, Nohra J, et al.Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.Transpl Int 2007;20:305-11
116. Halloran PF.Immunosuppressive drugs for kidney transplantation.N Engl J Med 2004;351:2715-29 (Pubitemid 39665325)